Shhh ... Don't Tell Anyone: Tips on NDAs

NDA

The Non-Disclosure Agreement (“NDA”) is a document that is very often prone to misuse in commercial practice. Often, when business teams from two companies get together, the first thing they do, almost as a box-checking measure, is toss over one company’s standard two-way NDA, without much thought as to whether the NDA should, in fact, be a two-way NDA or whether there is even any need for the NDA at all.

Continue reading this entry

Patent System after Oil States and SAS – What’s the future?

SCOTUS

On April 24th, the Supreme Court decided two important cases related to the United States Patent & Trademark Office’s inter partes review (IPR) proceedings for reconsidering the prior grant of a patent – Oil States Energy Services, LLC v. Greene’s Energy Group, LLC, No. 16-712 (Oil States) and SAS Institute Inc. v. Iancu, 16-969 (SAS).

Continue reading this entry

Fit for What Purpose? Understanding the Warranty of Fitness for Particular Purpose

contract

For manufacturing companies, some of the most important terms in any contract for the purchase or sale of goods are the warranties that apply to those goods.  This article will address one particular kind of warranty – the warranty of fitness for particular purpose.

Continue reading this entry

V4 Global B2B Tour and Medtech/Healthtech Startup Pitch Competition

AI

The mission of the Startup Campus V4 Global B2B Tour is to boost the discoverability of the regional startup ecosystem and highlight the economic and innovation potential of the Visegrad Group (V4), a cultural and political alliance of four Central European nations – Hungary, Poland, Slovakia, and the Czech Republic.

Continue reading this entry

Telemedicine Prescribing of Controlled Substances: the Dark Side of the New Congressional Bill

telemedicine

Congress has taken another step forward to require the federal Drug Enforcement Administration (DEA) to activate a special registration allowing physicians and nurse practitioners to prescribe controlled substances via telemedicine without an in-person exam.

The House Energy and Commerce Health subcommittee approved the Special Registration for Telemedicine Clarification Act of 2018, part of a larger package of legislation designed to give healthcare providers more tools to combat the opioid crisis and expand access to medical care.  POLITICO’s Morning eHealth reporter Darius Tahir first reported on the new legislation.

Continue reading this entry